trial evaluating the efficacy of omalizumab (Xolair ®) in idiopathic refractory severe solar urticaria
- Conditions
- Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
- Registration Number
- EUCTR2013-004910-16-FR
- Lead Sponsor
- Centre Hospitalier régional Universitaire de Besançon
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 10
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Omalizumab mechanism IgE pathway mast cell degranulation inhibition severe solar urticaria
Comparative effectiveness omalizumab vs antihistamines phototherapy refractory severe solar urticaria outcomes
Biomarkers predicting omalizumab response IgE levels basophil activation chronic solar urticaria
Omalizumab safety profile adverse events long-term treatment management chronic solar urticaria
Novel biologics ligelizumab dupilumab JAK inhibitors refractory chronic solar urticaria treatment